Table 4 Final diagnosis

Cancer, n/N (%)

50/135 (37.0)

41/76 (53.9)

0/76

9/59 (15.3)

0/59

< 1.10^-4

Organ, n/N (%)

Hematologic cancer

12/50 (24.0)

9/41 (22.0)

3/9 (33.3)

0.79

Upper digestive tract^#

3/50 (6.0)

2/41 (4.9)

1/9 (11.1)

NA

Lower digestive tract^§

5/50 (10.0)

3/41 (7.3)

2/9 (22.2)

NA

Liver

2 /50 (4.0)

2/41 (5.0)

0/9

NA

Pancreas

3/50 (6.0)

3/41 (7.3)

0/9

NA

Biliary tract

3/50 (6.0)

3/41 (7.3)

0/9

NA

Lung

7/50 (14.0)

6/41 (14.6)

1/9 (11.1)

NA

Breast

3/50 (6.0)

3/41 (7.3)

0/9

NA

Ovary

3/50 (6.0)

3/41 (7.3)

1/9 (11.1)

NA

Prostate

2/50 (4.0)

1/41 (2.4)

1/9 (11.1)

NA

Urinary tract

2/50 (4.0)

1/41 (2.4)

0/9

NA

Central nervous system

1/50 (2.0)

1/41 (2.4)

0/9

NA

Not known or uncertain

4 /50 (8.0)

4/41 (9.8)

0/9

NA

Histology, n/N(%)

Epithelial tumor

32/47 (68.1)

26/38(68.4)

6/9 (66.67)

1

Nonepithelial tumor

15/47(31.9)

12/38 (31.6)

3/9 (33.33)

1

- Neuroendocrine tumor

2/15 (12.5)

2/12 (16.7)

0/9

NA

- MPS

9/15 (56.3)

6/12 (50.0)

3/3 (100)

0.043

- LPS

1/15 (6.3)

1/12 (8.3)

0/3

NA

- MDS

2/15 (12.5)

2/12 (16.7)

0/3

NA

- GIST

1/15 (6.3)

1/12 (8.3)

0/3

NA

Stage, n/N(%)

I

5/42 (11.9)

3/33 (9.1)

2/9 (22.2)

NA

II

4/42 (9.5)

2/33 (6.1)

2/9 (22.2)

NA

III

2/42(4.8)

2/33 (6.1)

0/9

NA

IV

31/42 (73.8)

26/33 (78.8)

5/9 (55.6)

0.37

Benign disease, n/N(%)

81/135 (60.0)

35/76 (46.0)

46/59(78.0)

< 0.001

Infection

14/81 (17.3)

5/35 (14.3)

9/46 (19.6)

0.74

AID

45/81 (55.6)

22/35 (62.8)

23/46 (50)

0.35

Endocrinopathy

2/81(2.5)

1/35 (2.9)

1/46 (2.2)

NA

Digestive tract disorder

7/81 (8.6)

2/35 (5.7)

5/46 (10.9)

NA

Neurologic disorder

3/81 (3.7)

1/35 (2.9)

2/46 (4.3)

NA

Crystal arthropathy

2/81 (2.5)

2/35 (5.7)

0/46

NA

Adverse drug reactions

2/81(2.5)

0/35

2/46 (4.3)

NA

Other

6/81 (7.4)

2/35 (5.7)

4/46 (8.7)

NA

No final diagnosis, n/N(%)

4/135 (3.0)

0/35

4/50 (8.0)

NA